Lv5
890 积分 2024-11-29 加入
Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act
1天前
求助中
Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy
1天前
求助中
Tiragolumab plus atezolizumab and chemotherapy as first-line treatment for patients with unresectable oesophageal squamous cell carcinoma (SKYSCRAPER-08): a randomised, double-blind, placebo-controlled, phase 3 trial
1天前
已完结
Postmarket Drug Safety−Related Actions Before and After the US Food and Drug Administration Amendments Act
27天前
已关闭
A map of molecular drug targets and therapeutics for the US FDA-approved drugs: The impact of expedited regulatory pathways and first-in-class drug approvals on drug innovation
27天前
已完结
Use of FDA Expedited Programs and Development Timelines for New Molecular Entity Drug and New Biologic Approvals by Sponsor Experience
27天前
已完结
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials
29天前
已完结
Respiratory Disorders Associated with Antibody–Drug Conjugates: A Combined Analysis of the French and the WHO Pharmacovigilance Databases
1个月前
已完结
Radiotherapy for Unresectable Locally Advanced Non-Small Cell Lung Cancer: A Practical Multidisciplinary Approach to Challenging Scenarios from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee
1个月前
已关闭
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
1个月前
已完结
皖公网安备34019202002308
